cbd

U.S. Approves First Cannabis Plant-Derived Drug

GW Pharmaceuticals’ epilepsy treatment was approved this week by the FDA.

The U.S. health regulator approved GW Pharmaceuticals’ epilepsy treatment on Monday, making it the first cannabis-based drug to win approval in the country and opening floodgates for more research into the medicinal properties of cannabis.

The drug’s approval permits its use in patients aged two years and older with Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.

“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies,” said Food and Drug Administration Commissioner Scott Gottlieb.

The drug, Epidiolex, is made up of cannabidiol (CBD), one of the hundreds of molecules found in the marijuana plant, and contains less than 0.1 percent of tetrahydrocannabinol (THC), the psychoactive component that makes people high.

Share this post

分享在 facebook
分享在 google
分享在 twitter
分享在 linkedin
分享在 pinterest
分享在 print
分享在 email